The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ampio Pharmaceuticals, Inc. (NYSE: AMPE) who purchased common stock between December 29, 2020 and August 3, 2022. The action, which was filed in the United States District Court for the District of Colorado, alleges that the Company violated federal securities laws.
In particular, the Ampio lawsuit alleges that (i) defendants had inflated the Company’s true ability to successfully file a Biologics License Application (“BLA”) for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders have until October 17, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >